| Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript |
Seer, Inc. (NASDAQ:SEER ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Kelly Gura - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Rachel Vatnsdal - JPMorgan Operator Good day, and thank you for standing by. Welcome to Seer first quarter 2025 earnings conference call. |
seekingalpha.com |
2025-05-13 22:47:13 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates |
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-05-13 22:20:37 |
Czytaj oryginał (ang.) |
| Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook |
Revenue grew 37%, driven by increased product sales and service revenue Revenue grew 37%, driven by increased product sales and service revenue |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Seer to Report First Quarter 2025 Financial Results on May 13, 2025 |
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. |
globenewswire.com |
2025-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| SEER LAUNCHES CARBON FOCUSED DIVISION TO PRODUCE LICENSED BIOCHAR, MONETIZE AND TOKENIZE ASSETS AND CARBON CREDITS AND DEVELOP TURBINE BLADE TREATMENT TECHNOLOGY |
SEER Engages First Block AI to Assist in its Carbon Division Launch and Funding as well as Develop and Create SEER Security and Utility Tokens Backed by Assets and Fully-Insured Biochar Carbon Credits Broomfield, CO, March 31, 2025 (GLOBE NEWSWIRE) -- Strategic Environmental & Energy Resources, Inc. (SEER) (OTCQB: SENR), forms SEER Carbon Corp. as the entity to spearhead efforts to produce in-house biochar utilizing a patented technology under license from Biochar Now (www.biocharnnow.com) and create high-integrity, fully-insured carbon credits. SEER will transfer certain assets to SEER Carbon Corp. and then raise equity and growth capital through the sale of SEER Carbon security tokens. |
globenewswire.com |
2025-03-31 12:58:00 |
Czytaj oryginał (ang.) |
| After Plunging -16.59% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER) |
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-03-25 12:35:30 |
Czytaj oryginał (ang.) |
| After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER) |
Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-03-24 12:35:28 |
Czytaj oryginał (ang.) |
| Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-03-06 12:35:14 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript |
Seer, Inc. (NASDAQ:SEER ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Marta Zaremba - JPMorgan Jason Lai - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer Fourth Quarter and Full-Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-28 00:09:08 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates |
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago. |
zacks.com |
2025-02-27 21:40:20 |
Czytaj oryginał (ang.) |
| Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook |
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Seer to Participate in the TD Cowen 45th Annual Health Care Conference |
REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA. |
globenewswire.com |
2025-02-21 09:00:00 |
Czytaj oryginał (ang.) |
| Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025 |
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite |
globenewswire.com |
2025-02-20 09:00:00 |
Czytaj oryginał (ang.) |
| Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 |
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2025-02-13 18:15:00 |
Czytaj oryginał (ang.) |
| Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference |
REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA. |
globenewswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| SEER PARTNERS WITH DEVVSTREAM TO MONETIZE INSURED CARBON CREDITS ARISING OUT OF METHANE RENEWABLE ENERGY, CAPTURED OIL FIELD WELL EMISSIONS AND OTHER SEER PROJECTS |
SEER commits to an aggressive decarbonization and carbon credit monetization program, starting with its current MV Technology solutions and its planned biocarbon production facilities both domestic and international. |
globenewswire.com |
2024-12-12 11:30:00 |
Czytaj oryginał (ang.) |
| DevvStream Enters Biogas Market via Partnership with Methane Renewable Energy Leader |
Carbon Management Program by SEER and DevvStream will be centered around biogas capture and carbon sequestration through biocarbon, or biochar, production Companies plan to leverage over 150 existing SEER-affiliate biogas installations across North America with numerous multinational utility companies, food processors, brewers, and agriculture firms as well as future large-scale projects in the US and in the Kingdom of Saudi Arabia In addition to biogas and biocarbon production, the Program will also enable the generation of carbon credits from oil field emission reductions and sequestration projects Sacramento, California--(Newsfile Corp. - December 12, 2024) - DevvStream Corp. (NASDAQ: DEVS) ("DevvStream" or the "Company"), a leading carbon credit project co-development and generation firm specializing in technology-based solutions, and Strategic Environmental & Energy Resources, Inc. ("SEER"), a leading provider of environmental services, renewable fuels, and industrial waste management solutions, today announced a Carbon Management Program (the "Program") established to quantify and monetize high-quality carbon credits derived from SEER's cutting-edge technologies and projects, with a primary focus on biogas capture. Entry into the biogas industry expands the Company into an estimated $10 billion market in the United States, forecast to surpass $15 billion by 2030. |
newsfilecorp.com |
2024-12-12 09:30:00 |
Czytaj oryginał (ang.) |
| Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ |
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease |
globenewswire.com |
2024-11-21 18:05:00 |
Czytaj oryginał (ang.) |
| Seer to Participate in Upcoming November Investor Conferences |
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: |
globenewswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript |
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-06 23:00:22 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates |
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2024-11-06 21:00:38 |
Czytaj oryginał (ang.) |
| Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific |
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology |
globenewswire.com |
2024-11-06 18:03:00 |
Czytaj oryginał (ang.) |
| Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024 |
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite |
globenewswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024 |
Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale Seer's Proteograph™ Product Suite reveals new insights into Alzheimer's pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale |
globenewswire.com |
2024-10-21 11:00:00 |
Czytaj oryginał (ang.) |
| Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. |
globenewswire.com |
2024-08-22 20:05:00 |
Czytaj oryginał (ang.) |
| Seer Appoints Nicolas Roelofs to its Board of Directors |
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. |
globenewswire.com |
2024-08-14 20:05:00 |
Czytaj oryginał (ang.) |
| Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference |
REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA. |
globenewswire.com |
2024-08-09 11:00:00 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates |
Seer, Inc. (SEER) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.37 per share a year ago. |
zacks.com |
2024-08-08 23:20:32 |
Czytaj oryginał (ang.) |
| Seer to Report Second Quarter 2024 Financial Results on August 8, 2024 |
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-07-18 20:03:00 |
Czytaj oryginał (ang.) |
| SEER RECEIVES CONTRACT FROM BIOCHAR NOW FOR THE MANUFACTURING OF KILNS AND INTENDS TO OPEN A JV TEXAS BIOCHAR FACILITY |
SEER's product and manufacturing division, SEM, LLC, receives its first order from Biochar Now for the manufacturing of 33 kilns totaling approximately $600,000 |
globenewswire.com |
2024-06-14 15:05:00 |
Czytaj oryginał (ang.) |
| Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery |
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation |
globenewswire.com |
2024-06-11 15:11:00 |
Czytaj oryginał (ang.) |
| Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study |
Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects |
globenewswire.com |
2024-06-02 14:55:00 |
Czytaj oryginał (ang.) |
| Lab Instrument Industry Update - New Commercial Entrants |
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses. |
seekingalpha.com |
2024-05-23 13:17:40 |
Czytaj oryginał (ang.) |
| Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates |
Seer, Inc. (SEER) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.38 per share a year ago. |
zacks.com |
2024-05-08 23:46:07 |
Czytaj oryginał (ang.) |